The Japanese biotech reported net income of Y1.79 billion for the quarter ended 31 March, reversing a Y760 million loss a year earlier.
Revenue rose to Y11.26 billion from Y6.64 billion, while operating profit reached Y3.24 billion and pretax profit Y3.04 billion, both improving from losses last year.
Earnings per share were Y19.82, with diluted earnings of Y17.13. The company said the figures were prepared under IFRS accounting standards.
Is Nxera's partnership-heavy strategy the new winning formula for Japan's booming biotech market?
Can Nxera Pharma's milestone-fueled profit turnaround lead to sustainable long-term growth?